Urogen Pharma (NASDAQ:URGN) Issues Earnings Results

Urogen Pharma (NASDAQ:URGN) posted its earnings results on Wednesday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01, FiscalAI reports. The business had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI delivered $29.2M in Q1 revenue (>100% quarter-over-quarter growth) with the permanent J-code cited as a key catalyst for accelerated utilization.
• Commercial adoption is expanding: unique prescribers rose to 256 (from 102), repeat prescribers to 103 (from 32), PEFs and conversion times improved to ~30–35 days in Q1, and payer coverage now exceeds 95%.
• Pipeline momentum continues: the company plans an NDA for UGN-103 in H2 2026 (6-month durability data mid-year; potential 2027 approval), ongoing phase III for UGN-104, and an IND for UGN-501 with a Phase I start planned by year-end.
• Financials show progress (total Q1 revenue $51M, net loss narrowed to $23.6M, and cash of ~$140.3M), but Q1 SG&A jumped as expected and management declined to provide 2026 sales guidance for ZUSDURI, leaving near-term revenue visibility limited.

Urogen Pharma Stock Performance

NASDAQ URGN traded up $3.12 during trading on Wednesday, hitting $26.95. 2,116,151 shares of the company’s stock traded hands, compared to its average volume of 793,398. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $30.00. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -8.51 and a beta of 1.58. The business has a 50 day moving average of $20.37 and a 200-day moving average of $21.44.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Paradigm Biocapital Advisors LP purchased a new stake in Urogen Pharma in the third quarter valued at approximately $84,111,000. Soleus Capital Management L.P. bought a new position in Urogen Pharma during the second quarter valued at approximately $29,934,000. MPM Bioimpact LLC grew its position in Urogen Pharma by 597.3% during the fourth quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock valued at $22,047,000 after acquiring an additional 806,378 shares during the last quarter. TCG Crossover Management LLC bought a new position in Urogen Pharma during the third quarter valued at approximately $14,311,000. Finally, Voloridge Investment Management LLC bought a new position in Urogen Pharma during the third quarter valued at approximately $13,715,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on URGN shares. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. D. Boral Capital reiterated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Finally, Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.13.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.